Dr. Harshman on Earlier Use of Immunotherapy in RCC
May 18th 2018Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses moving immunotherapy earlier in the line of therapy for patients with renal cell carcinoma (RCC).